KRAS/STK11 co-mutations represent 25% of KRAS-mutant NSCLC, characterized by the low presence of tumor-infiltrating lymphocytes and reduced immune markers and PD-L1 levels. This evidence concerns the gene CD274 and non-small cell lung carcinoma.